Q4 2020
Released Jan 25, 2021, after the close
10-K filed Mar 11, 2021, 70 days after period end · 0001104659-21-034761
Q4 2020 · 10-K
Revenue$0.00$0.00 — vs Q4 2019no prior Q3 2020 on file
Net Income-$4.51M-$4.51M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—
Operating Incomederived-$4,801,674N/M
Operating Cash Flowderived-$3,684,029N/M
What the release said
The release
Same quarter
| Metric | Q4 2020 | Q4 2019dderived from reported figures | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$4.51M | -$3.29M | -$3.23M | -$5.33M |
| EPS Diluted | — | — | -$0.15 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR